Table 3.

Effectiveness endpoints in patients with at least one year of follow-up (discrepancies to n  = 37, 31, and 85 depend on missing values).

Endpoint	Mean at overall baseline	Crude (unadjusted) values
		LCH	GLH	LYH	P-heta
∆Weightb, kg	83
n		33	29	81
Mean (s.d.)		1.4 (8.2)	1.4 (6.6)	0.8 (5.5)	0.86
95% CI		−0.9 to 3.6	−1.0 to 3.8	−0.6 to 2.2	–
∆BMI, (kg/m2)	28.9
n		32	27	81
Mean (s.d.)		0.6 (3.0)	0.3 (2.0)	0.3 (2.0)	0.77
95% CI		−0.2 to 1.4	−0.6 to 1.13	−0.2 to 0.8	–
∆Total cholesterol mmol/L	5.9
n		11	12	33
Mean (s.d.)		−0.9 (0.9)	−0.6 (0.7)	−0.3 (1.2)	0.30
95% CI		−1.5 to −0.3	−1.2 to 0.1	−0.7 to 0.0
∆LDL, (mmol/L)	3.5
n		11	11	31
Mean (s.d.)		−0.6 (0.7)	−0.4 (0.7)	−0.2 (0.8)	0.40
95% CI		−1.0 to −0.1	−0.8 to 0.1	−0.5 to 0.1
∆HDL, (mmol/L)	1.4
n		11	12	33
Mean (s.d.)		−0.1 (0.3)	0.0 (0.1)	0.0 (0.4)	0.49
95% CI		−0.3 to 0.1	−0.2 to 0.1	−0.1 to 0.1
∆Triglycerides, (mmol/L)	2.0
n		11	12	32
Mean (s.d.)		−0.5 (0.8)	−0.4 (0.7)	0.2 (0.7)	0.02
95% CI		−0.9 to −0.03	−0.8 to 0.05	−0.1 to 0.4
∆F. Blood glucose, (mmol/L)	4.9
n		13	6	28
Mean (s.d.)		−0.1 (0.5)	0.5 (0.4)	0.3 (0.8)	0.21
95% CI		−0.5 to 0.3	−0.1 to 1.0	0.0 to 0.5
∆QoL-AGHDA items	10.9
n		20	18	42
Mean (s.d.)		−2.8 (5.3)	−5.1 (7.1)	−3.6 (6.3)	0.53
95% CI		−5.6 to 0.0	−8.0 to −2.1	−5.5 to −1.6
∆IGF-I s.d.	−2.0
n		14	15	39
Mean (s.d.)		1.9 (2.3)	2.2 (1.4)	2.1 (1.5)	0.93
95% CI		1.0 to 2.8	1.3 to 3.0	1.6 to 2.6
∆GH dose, (mg/day)	0.20
n		37	31	85
Mean (s.d.)		0.21 (0.25)	0.14 (0.48)	0.24 (0.27)	0.32
95% CI		0.10 to 0.31	0.03 to 0.25	0.17 to 0.31
1 year cross-sectional values
IGF-I s.d.S at 1 year visit
n		14	15	39
Mean (s.d.)		−0.5 (1.3)	0.3 (1.2)	0.1 (1.2)	0.13
95% CI		−1.1 to 0.1	−0.3 to 0.8	−0.2 to 0.5
% with ≤ −2 s.d.		5 (35.7)	1 (6.7)	3 (7.9)	>0.03
GH doseb mg/day at 1 year
n		37	31	85
Mean (s.d.)		0.39 (0.21)	0.46 (0.52)	0.41 (0.27)	0.63
95% CI		0.28 to 0.49	0.35 to 0.58	0.34 to 0.48

^a P-het: P-value heterogeneity between group means (alternative hypothesis: at least one group mean is different from the others). ^bNo effects remained significant after adjusted for age and gender. ∆: First-year delta (change).

∆, delta, AGHDA, assessment of GH deficiency in adults; GH, growth hormone; GLH, granulomatous hypophysitis; IGF-I s.d., insulin-like growth factor-1 s.d.; LCH, Langerhans cell histiocytosis; LYH, lymphocytic hypophysitis; QoL, quality of life.